Kabiri Rad Hamid, Mazaheri Mahta, Dehghani Firozabadi Ali
International Campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Avicenna J Med Biotechnol. 2018 Jan-Mar;10(1):29-33.
MicroRNAs (miRNAs) are implicated in various biological processes including anticoagulation. However, the modulation of miRNA by pharmacological intervention such as warfarin treatment in patients receiving warfarin has not been disclosed yet. The aim of this study work was to assess the effect of warfarin drug on expression level of mir-133a-3p in patients with mechanical heart valve replacement.
In this research, the expression level of miRNA-133a-3p was analyzed in Peripheral Blood Mononuclear Cells (PBMCs) from mechanical valve replacement patients who had received warfarin for at least 3 months continuously. Quantitative RT-PCR method was used for this assay.
Our findings indicated a significant diffrence between the rate of miR-133a-3p expression in individuals receiving warfarin and the control group (p<0.01). There was also a statistically significant difference in miR-133a-3p expression in patients with different ages (p<0.05) suggesting that the rate of miR-133a-3p expression in persons receiving warfarin is related to age. However, other variables like warfarin dose, International Normalized Ratio (INR), gender, and Body Mass Index (BMI) were not significantly effective on the miR-133a-3p experssion rate in individuals receving warfarin.
Based on our results, it can be concluded that miR-133a-3p is involved in the coagulation pathway. The recent result indicates that warfarin affects the expression of miR-133a. This expression may be potentially important for treatment by anticoagulants. Awareness of the time course of miRNA expression profile can improve efficiency of response to warfarin.
微小RNA(miRNA)参与包括抗凝在内的各种生物学过程。然而,在接受华法林治疗的患者中,华法林等药物干预对miRNA的调节作用尚未明确。本研究的目的是评估华法林药物对机械心脏瓣膜置换患者中mir-133a-3p表达水平的影响。
在本研究中,对连续接受华法林治疗至少3个月的机械瓣膜置换患者外周血单个核细胞(PBMC)中miRNA-133a-3p的表达水平进行分析。采用定量逆转录聚合酶链反应(qRT-PCR)方法进行检测。
我们的研究结果表明,接受华法林治疗的个体与对照组中miR-133a-3p的表达率存在显著差异(p<0.01)。不同年龄患者的miR-133a-3p表达也存在统计学显著差异(p<0.05),这表明接受华法林治疗的患者中miR-133a-3p的表达率与年龄有关。然而,其他变量如华法林剂量、国际标准化比值(INR)、性别和体重指数(BMI)对接受华法林治疗个体的miR-133a-3p表达率没有显著影响。
基于我们的结果,可以得出结论,miR-133a-3p参与凝血途径。最新结果表明,华法林会影响miR-133a的表达。这种表达可能对抗凝治疗具有潜在重要性。了解miRNA表达谱的时间进程可以提高对华法林反应的效率。